Anifrolumab
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
Pressure score
63
Momentum score
5
Why This Matters
Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.
Competitive Assessment
- Threat type
- regulatory competitor
- Development stage
- Stage unknown
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Moderate share risk if competitor advances before the signal sponsor establishes label leadership.
Strategic Action
Align with signal posture: monitor. Monitor regulatory competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
Roche's Anifrolumab directly references the same indication focus (Immunology · Systemic Lupus Erythematosus) as this signal.
Source: Humanexa Signals
No public source document URL on file.
Related Signal
AstraZeneca's Anifrolumab Study for Systemic Lupus Erythematosus Underway
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #1 of 2
Roche
4 competitive findings
Top program: Anifrolumab
- Pressure
- 65
- Momentum
- 5
- Threat
- regulatory competitor
- Stage
- Stage unknown
65RocheMediumAnifrolumab·Stage unknown
Bristol Myers Squibb
1 competitive finding
Top program: Anifrolumab
- Pressure
- 52
- Momentum
- 5
- Threat
- direct competitor
- Stage
- Stage unknown
52Bristol Myers SquibbMediumAnifrolumab·Stage unknown